Topical Nonsteroidal Anti-Inflammatory Drugs in the Treatment of Osteoarthritis

Total Page:16

File Type:pdf, Size:1020Kb

Topical Nonsteroidal Anti-Inflammatory Drugs in the Treatment of Osteoarthritis REVIEW Topical nonsteroidal anti-inflammatory drugs in the treatment of osteoarthritis Zahi Touma, Lan Chen Osteoarthritis is the most common degenerative joint disease and is particularly common in & Thurayya Arayssi† the elderly. Topical nonsteroidal anti-inflammatory drugs (NSAIDs) may represent a rational †Author for correspondence treatment in this situation because of their favorable side-effect profile. The majority of American University of topical NSAIDs decrease pain and relieve functional disability caused by osteoarthritis over Beirut Medical Center, the short term, however, there are insufficient data for their long-term efficacy. Department of Internal Medicine, Division of Rheumatology, 3 Dag Osteoarthritis (OA) is the most common disease patients with OA of the knees [9]. Other interven- Hammarskjöld Plaza, of synovial joints, associated with locomotor tions include the use of assistive devices (cane or 8th floor, New York, pain, chronic disability and morbidity [1]. It is crutch), application of braces and patellar taping NY, 10017, USA estimated by the WHO to be the fourth most and/or orthotics, especially in patients with insta- Tel.: +1 961 135 0000 Ext: 5383; important cause of disability among women and bility of the knee and varus malalignment [8,10,11]. Fax: +1 961 136 5189; the eighth amongst men [2]. Its prevalence and Participation in patient self-management pro- [email protected] incidence are projected to rise as the elderly pro- grams and personalized social support through portion of the population increases, which will telephone contact have also been shown to help have a significant impact on society [3]. The in decreasing pain and improving function in onset of the disease most commonly occurs patients with OA [10]. between the age of 50 and 60 years and fre- Acupuncture has been evaluated in rando- quently affects the hands, spine, knees and hips mized controlled trials and been shown to [4]. Involvement of the wrists, elbows, ankles and provide added benefit in patients with knee OA shoulders is uncommon [5]. The majority of per- with a favorable safety profile [12,13]. sons show radiographic evidence of OA by Topical traditional Chinese medicine 65 years of age, although most are asymptomatic (TTCMs) and other alternative remedies are still [6]. In the Framingham study, for example, 30% widely used, especially in Chinese and other eth- of patients aged over 60 years had radiological nic communities. When all the ‘modern’ prepa- evidence of OA of the knee, which was not rations have been exhausted, some ‘old remedies’ always symptomatic [4]. have been explored by patients [14]. Litt has OA was previously thought to be a normal offered a list of 73 alternative topical measures consequence of aging, thereby linked to the term that are often beneficial, mostly for dermatologic degenerative joint disease. It is now recognized disorders [15]. TTCMs have many varieties. A that OA results from a complex interplay of common misconception is that TTCM is a com- multiple factors, including joint integrity, genet- plicated, exotic art. Difficulties in understanding ics, metabolic, local inflammation, mechanical these measures are due first to more than one forces, previous injury of a joint, and cellular and ingredient in one formulation, second to the biochemical processes [7,8]. myriad of preparations available and third due to To date, there are no means to prevent the labeling, with brands such as Tiger Balm, occurrence of OA. Thus, treatment is directed 3-Snake Oil and Dragon Balm. First and fore- towards pain relief, improving function and most, it must be understood that brand names health-related quality of life [8]. A combination are just brand names. The names are symbolic of nonpharmacologic (Box 1), pharmacologic [14]. Tiger Balm and 3-Snake Oil do not contain (Table 1) and surgical (Box 2) treatment is usually any material from either of these animals. Keywords: diclofenac, needed and should be individualized according Indeed, TTCMs are mixtures containing many ibuprofen, ketoprofen, meta-analysis, osteoarthritis, to patient needs, presence of comorbidities and herbs, ranging from three to 20 different types. piroxicam, randomized drug–drug interactions. Mixtures are based on the concept of traditional controlled trials, topical Chinese medicine. The formulations use differ- nonsteroidal anti- inflammatory drugs Nonpharmacologic treatment ent ingredients to balance the body and to bal- Current treatment guidelines recommend the ance the opposite properties of different herbals. part of combination of weight loss and exercise pro- However, all these myriads of preparations can grams to reduce pain and improve function in be grouped into three classes, according to usage. 10.2217/17460816.2.2.163 © 2007 Future Medicine Ltd ISSN 1746-0816 Future Rheumatol. (2007) 2(2), 163–175 163 REVIEW – Touma, Chen & Arayssi Box 1. Nonpharmacologic therapy for be soothing. They usually are not irritating to patients with osteoarthritis. the skin unless the patients are allergic to these ingredients. Other paste preparations are mix- • Patient education tures of various herbals with a petrolatum base. • Self-management programs Zingiber officinale rhizoma, Polygonum multiflo- • Telephone contact rum radix, Peonia lactiflora radix, rhizoma et • Weight loss (if overweight) radix notopterygii, myrrha and other herbals • Physical therapy and aerobic exercise are commonly used for rheumatic pain, a • Patellar taping • Corrective footwear, bracing, joint protection, bi-syndrome in TTCM. None of these have lateral-wedged insoles (for genu varum) been assessed in controlled trials available in • Assistive devices for activities of daily living english [14,17]. • Laser • Pulsed electromagnetic field, ultrasound, Pharmacologic treatment transcutaneous electrical nerve stimulation Paracetamol, up to 4 g/day, remains the most • Acupuncture commonly prescribed drug in patients with mild- • Nutrients, herbal remedies, vitamins/minerals to-moderate pain. A meta-analysis published in •Spa 2004 confirmed the efficacy of acetaminophen in relieving pain due to OA, which should be the In each class, the ingredients revolve around a first-line treatment, reserving nonsteroidal common theme, with only minor differences. anti-inflammatory drugs (NSAIDs) for patients The three classes are: who do not respond [18]. • Oils, ointments, pastes for aches and pains; Both classical NSAIDs and cyclo-oxygenase (Cox)-2 inhibitors are used commonly and are • Oils, ointments, pastes for orthopedic injuries; more effective than placebo and acetaminophen • Lotions and ointments for skin diseases. in reducing pain and functional disabilities in Here, only the first class will be briefly patients with OA of knees and hips [19,20]. This summarized [14,16]. superiority of NSAIDS over acetaminophen, The classic example of class 1 TTCMs used however, is modest and because of the high inter- for rheumatic pain is Tiger Balm [17]. It is an individual variability in patient response to both oil-based balm containing camphor, menthol of these drug classes, it is impossible to predict and one or more essential oils, such as cinna- the patient’s response to them [8,21]. mon oil, oil of clove, cassia oil, citronella oil, oil Opiate analgesic agents, including tramadol, of lavender or cajuput oil. These are compound can also be used and may be of benefit in together in a base oil or petrolatum. It can thus patients with severe pain resistant to NSAIDs or be appreciated that the formulation is meant to in those who have contraindication to treatment with other drugs [11]. Glucosamine and chondroitin are natural Table 1. Pharmacologic therapy of osteoarthritis. substances derived from animal products that Route Pharmacologic agent have acquired substantial popularity in the Oral therapy Acetaminophen treatment of OA [22]. The most important merit NSAIDs is their safety, although their mechanisms of Cyclooxygenase-2 action are unclear [11]. In a 2003 meta-analysis that included 15 randomized, double-blind, Nonacetylated salicylate placebo-controlled trials that assessed either glu- Tramadol cosamine or chondroitin on structure modifica- Opioids tion of knee or hip OA, glucosamine was found Glucosamine sulfate to have a positive effect in reducing joint space Chondroitin sulfate narrowing [23]. In a recently published rand- Intra-articular therapy Glucocorticoids omized controlled trial of glucosamine and Hyaluronan chondroitin, the drugs were not helpful in effec- Tidal irrigation tively reducing pain in patients with OA of the knees. Exploratory analyses, however, suggest Topical therapy NSAIDs that the combination may be effective in the Capsaicin subgroup of patients with moderate-to-severe NSAID: Nonsteroidal anti-inflammatory drug. knee pain [24]. 164 Future Rheumatol. (2007) 2(2) futurefuture sciencescience groupgroup Topical nonsteroidal anti-inflammatory drugs in the treatment of osteoarthritis – REVIEW Box 2. Surgical treatment for patients with osteoarthritis. hospital with GI problems for regular users of oral NSAIDs is 1.3–1.6% annually [30]. In the • Arthroscopic management USA, GI tract bleeding secondary to NSAIDs – Lavage accounts for 41,000 hospitalization and 3300 – Debridement deaths each year [31]. Additionally, approxi- – Abrasion arthroplasty mately 40% of hospital admissions with upper – Subchondral penetration procedures (drilling and microfracture) GI bleeding, and 40% of associated deaths in – Laser/thermal chondroplasty older
Recommended publications
  • Scottish Medicines Consortium
    Scottish Medicines Consortium diclofenac 1% gel patches (Voltarol Gel PatchÒ) No. (199/05) Novartis 9 September 2005 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following a full submission Diclofenac 1% gel patch (Voltarol Gel PatchÒ) is not recommended for use within NHS Scotland for the local symptomatic treatment of pain in epicondylitis and ankle sprain. Diclofenac gel patch provides analgesia similar to that obtained with a topical gel formulation of this drug. However, on a gram per gram basis, patches cost over 40% more than the gel formulation. Overleaf is the detailed advice on this product. Chairman, Scottish Medicines Consortium 1 Diclofenac 1% gel patch (Voltarol Gel Patch®) Licensed indication under review Local symptomatic treatment of pain in epicondylitis and ankle sprain in adults. Dosing information under review Epicondylitis: one application morning and night for up to fourteen days. Ankle sprain: one application per day for up to three days. UK launch date 1 October 2005 Comparator medications Conditions included in the indications of diclofenac 1% gel patch, epicondylitis (tennis elbow) and ankle sprain could be treated topically with gel formulations of other non-steroidal anti- inflammatory drugs (NSAIDs), including diclofenac, ibuprofen, piroxicam, ketoprofen and felbinac or systemically with oral formulations of these drugs
    [Show full text]
  • Diclofenac Topical Patch Gel Solution Monograph
    Diclofenac Topical Patch, Gel and Solution National Drug Monograph March 2016 VHA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives The purpose of VA PBM Services drug monographs is to provide a focused drug review for making formulary decisions. Updates will be made when new clinical data warrant additional formulary discussion. Documents will be placed in the Archive section when the information is deemed to be no longer current. FDA Approval Information Description/Mechanism of Action Diclofenac is the only nonsteroidal antiinflammatory drug (NSAID) approved in the U.S. for topical application. The mechanism of diclofenac is believed to be inhibition of prostaglandin synthesis, primarily by nonselectively inhibiting cyclooxygenase. The agents covered in this review are the four diclofenac topical products approved for analgesic purposes: Diclofenac epolamine / hydroxyethylpyrrolidine patch (DEHP) 1.3% approved in January 2007 Diclofenac sodium topical gel 1%, approved in October 2007 Diclofenac sodium topical solution 1.5% with dimethyl sulfoxide (DMSO, 45.5% w/w), approved in November 2009 Diclofenac sodium topical solution 2% with dimethyl sulfoxide (DMSO, 45.5% w/w), approved in January 2014 Indication(s) Under Review in this document (may include off Solution 1.5% Solution 2% label) Patch 1.3% Gel 1% (Drops) (MDP) Topical treatment Relief of the pain of Treatment of signs Treatment of the Also see Table 1 Product Descriptions of acute pain due osteoarthritis of joints and symptoms of pain of below. to minor strains, amenable to topical osteoarthritis of the osteoarthritis of sprains, and treatment, such as the knee(s) the knee(s) contusions knees and those of the hands.
    [Show full text]
  • Ketoprofen 2.5% Gel: a Clinical Overview
    European Review for Medical and Pharmacological Sciences 2011; 15: 943-949 Ketoprofen 2.5% gel: a clinical overview S. COACCIOLI Rheumatology Unit, Santa Maria General Hospital, Terni (Italy) Abstract. – Ketoprofen (KP), a non- therefore, with fewer serious adverse events steroidal anti-inflammatory drug (NSAID), pos- (AEs)2. Current guidelines produced by the Euro- sesses analgesic, antipyretic and anti-inflamma- pean League Against Rheumatism (EULAR) and tory properties. Oral KP is widely used in mus- culoskeletal pain and inflammation in muscles the Osteoarthritis Research Society International and joints, including arthritis pain, osteoarthritis, (OARSI) suggest that topical NSAIDs are pre- stiffness of the joints, soft tissue rheumatism, ferred over oral NSAIDs for patients with mild to and sports injuries. In common with all NSAIDs, moderate knee or hand OA with few affected oral KP has been associated with systemic ad- joints, and/or a history of sensitivity to oral verse events and in particular gastrointestinal NSAIDs3,4. The favourable benefit/risk ratio of disorders. Topical application of the active ingre- dient is locally effective and at the same time topical NSAIDs has been further confirmed by a minimises the risk of systemic adverse events. recent Cochrane meta-analysis of 47 randomized Pharmacokinetic studies show that serum levels studies5. Because there are a number of topical of the active ingredient following topical KP formulations of NSAIDs currently available, 2.5% gel are less than 1% of those reported after there is a need to summarize the evidence sup- oral dosing, thereby providing good levels of porting the effectiveness and safety of each for- pain relief without the systemic adverse events mulation.
    [Show full text]
  • Allergic and Photoallergic Contact Dermatitis to Topical Non-Steroidal Anti-Inflammatory Drugs: a Case Series from Turkey
    CONTACT DERMATITIS AND OCCUPATIONAL DERMATOSES ALLERGIC AND PHOTOALLERGIC CONTACT DERMATITIS TO TOPICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS: A CASE SERIES FROM TURKEY E Ozkaya (1) - A Kutlay (1) Istanbul University Istanbul Medical Faculty, Dermatology, Istanbul, Turkey (1) Background: Topical non-steroidal anti-inflammatory drugs (NSAIDs) are widely used, mainly for soft tissue pain and injury. Allergic contact dermatitis (ACD) and photoallergic contact dermatitis (PACD) from topical NSAIDs have been reported with an increasing incidence. Ketoprofen seems to be the major culprit drug, followed by etofenamate and bufexamac in many European countries. There are only limited data on this subject in Turkey. Observation: Out of 2375 consecutively patch tested patients in our clinic between 1996 and 2017, 13 patients (7 male, 6 female, age range: 21-81, median: 56 years) (0.5%) were diagnosed with topical NSAID-induced ACD/PACD. Patients were patch tested (n=13) and photopatch tested (n=4) with the suspected topical preparations as is, and with the active (n=4) and inactive ingredients, when available, in addition to the European baseline series. Etofenamate (tested in a dilution series of 1%-5%-10% in petrolatum and aqua) was the leading culprit drug in 8 patients (62%), followed by ketoprofen (n=2), diclofenac (n=2), and diethylamine salicylate & naproxen (n=1). The main diagnosis was ACD whereas PACD was diagnosed in 2 patients from etofenamate and ketoprofen. Concomitant positive reaction were observed with inactive ingredients such as benzyl alcohol in etofenamate, and neroli oil in ketoprofen preparations, respectively. Cross-reaction to fragrances (fragrance mix I, balsam of Peru, cinnamic alcohol/aldehyde) was present in both patients with ketoprofen allergy.
    [Show full text]
  • Analgesic Efficacy and Safety of Transdermal and Oral Diclofenac in Postoperative Pain Management Following Dental Implant Placement
    Analgesic efficacy and safety of transdermal and oral diclofenac in postoperative pain management following dental implant placement Raja Rajeswari S., MDS ¢ Triveni M. Gowda, MDS ¢ Tarun A.B. Kumar, MDS ¢ Dhoom S. Mehta, MDS Kanchan Arya, MDS The aim of this study was to compare the efficacy and ehabilitation of partially and completely edentulous safety of transdermal and oral routes of diclofenac for areas with dental implants is well established, with postoperative pain management in patients undergo- numerous advantages over conventional procedures. ing dental implant placement. Twenty systemically R A recent meta-analysis demonstrated a 95.2% survival rate and healthy, partially edentulous patients who required 84.9% success rate in single-crown–supported implants, signi- 1 dental implants bilaterally in the mandibular first molar fying the predictability of this treatment modality. The pain region were included. While the patient was under local following implant surgery is categorized generally as mild to anesthesia, an implant was placed in the mandibular moderate and generally is at its maximum level 5-6 hours post- 2 first molar region of one quadrant. After a minimum postoperatively. If appropriate surgical guidelines—including of 4 weeks, an implant was placed in the contralateral precise incision, gentle tissue handling, heat control with quadrant under local anesthesia. Patients were pre- copious irrigation during osteotomy preparation, intermittent scribed 50 mg of oral diclofenac, taken twice daily for 3 drilling pressure, and end-to-end closure of sutures—are fol- days, following implant placement on the first side and lowed prudently, postoperative pain can be mitigated consider- a 100-mg diclofenac transdermal patch, placed once ably.
    [Show full text]
  • Composition for Use in Treating and Preventing Inflammation Related Disorder
    (19) TZZ 54¥¥7A_T (11) EP 2 543 357 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 09.01.2013 Bulletin 2013/02 A61K 9/00 (2006.01) A61K 47/36 (2006.01) (21) Application number: 11173000.8 (22) Date of filing: 07.07.2011 (84) Designated Contracting States: (72) Inventor: Lin, Shyh-Shyan AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Taipei (TW) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR (74) Representative: Becker Kurig Straus Designated Extension States: Bavariastrasse 7 BA ME 80336 München (DE) (71) Applicant: Holy Stone Healthcare Co.,Ltd. Taipei City (TW) (54) Composition for use in treating and preventing inflammation related disorder (57) The presentinvention isrelated to ause fortreat- ease, coeliac disease, conjunctivitis, otitis, allergic rhin- ing and preventing inflammation related disorder of a itis, gingivitis, aphthous ulcer, bronchitis, gastroesopha- composition containing a drug and hyaluronic acid (HA) geal reflux disease (GERD), esophagitis, gastritis, en- or HA mixture, whereas the HA or the HA mixture as a teritis, peptic ulcer, inflammatory bowel disease (IBD), delivery vehicle can be a formulation including at least Crohn’s Disease, irritable bowel syndrome (IBS), intes- two HAs having different average molecular weights. The tinal inflammation or allergy, urethritis, cystitis, vaginitis, composition has been demonstrated to be capable of proctitis, eosinophilic gastroenteritis, or rheumatoid ar- reducing the therapeutic dose of a drug on the treatment thritis. and prevention of inflammation related disorders is acute inflammatory disease, chronic obstructed pulmonary dis- EP 2 543 357 A1 Printed by Jouve, 75001 PARIS (FR) 1 EP 2 543 357 A1 2 Description alleviate pain by counteracting the cyclooxygenase (COX) enzyme.
    [Show full text]
  • Inflammatory Drugs (Nsaids) for People with Or at Risk of COVID-19
    Evidence review Acute use of non-steroidal anti- inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 Publication date: April 2020 This evidence review sets out the best available evidence on acute use of non- steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19. It should be read in conjunction with the evidence summary, which gives the key messages. Evidence review commissioned by NHS England Disclaimer The content of this evidence review was up-to-date on 24 March 2020. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up-to-date information. For details on the date the searches for evidence were conducted see the search strategy. Copyright © NICE 2020. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3763-9 Contents Contents ...................................................................................................... 1 Background ................................................................................................. 2 Intervention .................................................................................................. 2 Clinical problem ........................................................................................... 3 Objective ...................................................................................................... 3 Methodology ................................................................................................ 4 Summary of included studies
    [Show full text]
  • Innovations from 'Down-Under': a Focus on Prescription to Non-Prescription Medicine Reclassification in New Zealand and Australia
    ORIGINAL ARTICLE SelfCare 2012;3(5):88-107 Advancing the study&understanding of self-care INNOVATIONS FROM ‘DOWN-UNDER’: A FOCUS ON PRESCRIPTION TO NON-PRESCRIPTION MEDICINE RECLASSIFICATION IN NEW ZEALAND AND AUSTRALIA NATALIE GAULD*, FIONA KELLY**, LYNNE EMMERTON†, LINDA BRYANT††, STEPHEN BUETOW‡ * PhD Candidate, Department of General Practice and Primary Health Care, University of Auckland, New Zealand **Honorary Senior Lecturer, School of Pharmacy, University of Auckland, New Zealand †Associate Professor, School of Pharmacy, Curtin Health Innovation Research Institute, Perth, Western Australia †† Honorary Lecturer, Department of General Practice and Primary Health Care, University of Auckland, New Zealand ‡Associate Professor, Department of General Practice and Primary Health Care, University of Auckland, New Zealand ABSTRACT BACKGROUND: Australia and New Zealand (NZ) contribute to the international trend of medicines reclassification from prescription to non-prescription availability (switch). Both countries have been acknowledged as being as advanced or even more so than the United Kingdom (UK) in availability of medicines without prescription, despite not making some of the recent innovative UK switches. OBJECTIVE: To derive a measure of progressiveness in switch; to compare the progressiveness of switch between NZ and Australia; and to compare NZ and Australia switch activity with the UK. METHODS: Records of medicines classification meetings in Australia and NZ from 2000 to 2011 were analysed with respect to all switch considerations (whether approved or not approved). Switches in Australia and NZ were compared with those in the UK. A new measure, ‘innovative switches’, was developed to provide a useful measure of switch progress. RESULTS: Australia demonstrated ‘switch innovation’ in the early 2000s, including the ‘first-in-world’ switch of orlistat, but has slowed down since.
    [Show full text]
  • A Thesis Entitled Design, Optimization and Evaluation of a Novel Emulgel
    A Thesis entitled Design, Optimization and Evaluation of a Novel Emulgel of Ibuprofen for Enhanced Skin Delivery using Formulating for Efficacy™ software by Aastha Chadha Submitted to the Graduate Faculty as partial fulfillment of the requirements for the Master of Science Degree in Pharmaceutical Sciences Industrial Pharmacy ________________________________________ Gabriella Baki, Ph.D., Committee Chair ________________________________________ Caren L. Steinmiller, Ph.D., Committee Member ________________________________________ Jerry Nesamony, Ph.D., Committee Member ________________________________________ Dr. Amanda Bryant-Friedrich, Dean College of Graduate Studies The University of Toledo May, 2018 Copyright 2018, Aastha Chadha This document is copyrighted material. Under copyright law, no parts of this document may be reproduced without the expressed permission of the author. An Abstract of Design, Optimization and Evaluation of a Novel Emulgel of Ibuprofen using Formulating for Efficacy™ Software by Aastha Chadha Submitted to the Graduate Faculty as partial fulfillment of the requirements for the Master of Science Degree in Pharmaceutical Sciences Industrial Pharmacy The University of Toledo May 2018 Development of novel formulations present unique challenges in selecting the optimum formulation type for a given active ingredient. The topical route has long been used for delivering drugs directly to the affected target site through the skin. Current approaches in design and optimization of topical formulations necessitate extensive decisions in choosing the right components for the formulation to achieve high safety, clinical efficacy, and patient compliance. It is a resource-intensive process, which involves a certain degree of hit-and-trial on the part of the formulator. Solubility of the active ingredient in the vehicle and the skin is an important parameter in selecting and optimizing vehicle components for topical formulation development.
    [Show full text]
  • WO 2013/020527 Al 14 February 2013 (14.02.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/020527 Al 14 February 2013 (14.02.2013) P O P C T (51) International Patent Classification: (74) Common Representative: UNIVERSITY OF VETER¬ A61K 9/06 (2006.01) A61K 47/32 (2006.01) INARY AND PHARMACEUTICAL SCIENCES A61K 9/14 (2006.01) A61K 47/38 (2006.01) BRNO FACULTY OF PHARMACY; University of A61K 47/10 (2006.01) A61K 9/00 (2006.01) Veterinary and Pharmaceutical Sciences Brno Faculty Of A61K 47/18 (2006.01) Pharmacy, Palackeho 1/3, CZ-61242 Brno (CZ). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/CZ20 12/000073 kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (22) Date: International Filing BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, 2 August 2012 (02.08.2012) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (25) Filing Language: English HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (26) Publication Language: English ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (30) Priority Data: NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, 201 1-495 11 August 201 1 ( 11.08.201 1) SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, 2012- 72 1 February 2012 (01.02.2012) TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, 2012-5 11 26 July 2012 (26.07.2012) ZW.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2005/0249806A1 Proehl Et Al
    US 2005O249806A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0249806A1 Proehl et al. (43) Pub. Date: Nov. 10, 2005 (54) COMBINATION OF PROTON PUMP Related U.S. Application Data INHIBITOR, BUFFERING AGENT, AND NONSTEROIDAL ANTI-NFLAMMATORY (60) Provisional application No. 60/543,636, filed on Feb. DRUG 10, 2004. (75) Inventors: Gerald T. Proehl, San Diego, CA (US); Publication Classification Kay Olmstead, San Diego, CA (US); Warren Hall, Del Mar, CA (US) (51) Int. Cl." ....................... A61K 9/48; A61K 31/4439; A61K 9/20 Correspondence Address: (52) U.S. Cl. ............................................ 424/464; 514/338 WILSON SONS IN GOODRICH & ROSAT (57) ABSTRACT 650 PAGE MILL ROAD Pharmaceutical compositions comprising a proton pump PALO ALTO, CA 94304-1050 (US) inhibitor, one or more buffering agent and a nonsteroidal ASSignee: Santarus, Inc. anti-inflammatory drug are described. Methods are (73) described for treating gastric acid related disorders and Appl. No.: 11/051,260 treating inflammatory disorders, using pharmaceutical com (21) positions comprising a proton pump inhibitor, a buffering (22) Filed: Feb. 4, 2005 agent, and a nonsteroidal anti-inflammatory drug. US 2005/0249806 A1 Nov. 10, 2005 COMBINATION OF PROTON PUMP INHIBITOR, of the Stomach by raising the Stomach pH. See, e.g., U.S. BUFFERING AGENT, AND NONSTEROIDAL Pat. Nos. 5,840,737; 6,489,346; and 6,645,998. ANTI-NFLAMMATORY DRUG 0007 Proton pump inhibitors are typically prescribed for Short-term treatment of active duodenal ulcers, gastrointes CROSS REFERENCE TO RELATED tinal ulcers, gastroesophageal reflux disease (GERD), Severe APPLICATIONS erosive esophagitis, poorly responsive Symptomatic GERD, 0001.
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of - Medicines belonging to the ATC group M01 (Antiinflammatory and antirheumatic products) Table of Contents Page INTRODUCTION 6 DISCLAIMER 8 GLOSSARY OF TERMS USED IN THIS DOCUMENT 9 ACTIVE SUBSTANCES Phenylbutazone (ATC: M01AA01) 11 Mofebutazone (ATC: M01AA02) 17 Oxyphenbutazone (ATC: M01AA03) 18 Clofezone (ATC: M01AA05) 19 Kebuzone (ATC: M01AA06) 20 Indometacin (ATC: M01AB01) 21 Sulindac (ATC: M01AB02) 25 Tolmetin (ATC: M01AB03) 30 Zomepirac (ATC: M01AB04) 33 Diclofenac (ATC: M01AB05) 34 Alclofenac (ATC: M01AB06) 39 Bumadizone (ATC: M01AB07) 40 Etodolac (ATC: M01AB08) 41 Lonazolac (ATC: M01AB09) 45 Fentiazac (ATC: M01AB10) 46 Acemetacin (ATC: M01AB11) 48 Difenpiramide (ATC: M01AB12) 53 Oxametacin (ATC: M01AB13) 54 Proglumetacin (ATC: M01AB14) 55 Ketorolac (ATC: M01AB15) 57 Aceclofenac (ATC: M01AB16) 63 Bufexamac (ATC: M01AB17) 67 2 Indometacin, Combinations (ATC: M01AB51) 68 Diclofenac, Combinations (ATC: M01AB55) 69 Piroxicam (ATC: M01AC01) 73 Tenoxicam (ATC: M01AC02) 77 Droxicam (ATC: M01AC04) 82 Lornoxicam (ATC: M01AC05) 83 Meloxicam (ATC: M01AC06) 87 Meloxicam, Combinations (ATC: M01AC56) 91 Ibuprofen (ATC: M01AE01) 92 Naproxen (ATC: M01AE02) 98 Ketoprofen (ATC: M01AE03) 104 Fenoprofen (ATC: M01AE04) 109 Fenbufen (ATC: M01AE05) 112 Benoxaprofen (ATC: M01AE06) 113 Suprofen (ATC: M01AE07) 114 Pirprofen (ATC: M01AE08) 115 Flurbiprofen (ATC: M01AE09) 116 Indoprofen (ATC: M01AE10) 120 Tiaprofenic Acid (ATC:
    [Show full text]